EMERGING REAL-WORLD DATA FROM A PAN-EUROPEAN EVALUATION OF A NEW FULL RANGE OF FOCUS INTRAOCULAR LENS (IOL): COMPARISON OF VISUAL OUTCOMES WITH PUBLISHED RESULTS FOR OTHER EDOF AND TRIFOCAL IOLS

To report on emerging real-world data and evaluate the visual performance of a new full range of focus intraocular lens (IOL) across multiple European centers, and to compare its outcomes with published results for other extended depth of focus (EDOF) and trifocal IOLs.

Miranza Santander (Spain), SpaMedica Leeds (United Kingdom), OSG Fürth (Germany), OSG Siegburg (Germany) – all part of the veonet Group.

A retrospective evaluation was conducted including clinical outcomes of patients undergoing cataract surgery and implanted with a new full range of focus IOL (RayOne Galaxy, Rayner, Worthing, UK). Data collected included preoperative and postoperative spherical equivalent (SEQ), monocular uncorrected distance, intermediate and near visual acuity (UDVA, UIVA, UNVA, respectively). Data were collected at varying stablished postoperative time points across sites and descriptively compared to data from peer-reviewed literature on other contemporary EDOF and trifocal IOLs.

A total of 68 eyes from 38 patients with a mean age of 68 ± 8 years were analyzed. The mean postoperative spherical equivalent was –0.15 ± 0.45 D, indicating optimum refractive predictability relative to the mean target of 0.11 ± 0.17 D, with 94% of eyes within ±1.00D after surgery. Treatments were effective at different distances with 96%, 91% and 50% of eyes reaching uncorrected VA of 20/25 at distance, intermediate and near, respectively. The postoperative mean monocular UDVA was 0.02 ± 0.14 logMAR, UIVA 0.07 ± 0.11 logMAR, and UNVA 0.08 ± 0.10 logMAR. Corrected distance vision was significantly improved (p<0.05) after surgery with a mean postoperative monocular CDVA of –0.01 ± 0.11 logMAR and a mean preoperative CDVA of 0.33 ± 0.26 logMAR, indicating a strong safety profile.

Direct statistical comparison with published outcomes of modern EDOF and trifocal IOLs was not performed, as comparative datasets originate from heterogeneous study designs and follow-up protocols. However, when qualitatively compared, the new lens showed distance VA comparable to both, a somewhat superior intermediate performance relative to EDOFs, and near vision slightly inferior to that achieved with certain trifocals, while maintaining a very similar level of predictability.

This pan-European evaluation of emerging clinical data shows the safety and predictability of the procedure and suggests that the new full range of focus IOL provides a balanced level of visual performance across all distances comparable to that of current EDOF and trifocal technologies. Despite the limitations of cross-study comparisons and varying follow-up intervals, the lens appears to offer a viable alternative for patients seeking spectacle independence following cataract surgery.